Novartis' Rare Blood Disorder Therapy Aces Second Late-Stage Trial

• Novartis AG's (NYSE: NVS) Phase 3 APPOINT-PNH study of iptacopan in complement-inhibitor-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH) met its primary endpoint.

• Topline results showed that a significant proportion of patients treated with iptacopan (200 mg twice daily) achieved clinically meaningful hemoglobin-level increases of 2 g/dL or more from baseline without blood transfusions at 24 weeks.

• In the study, the safety profile of iptacopan monotherapy was consistent with previously reported data.

• Topline results for the pivotal Phase 3 APPLY-PNH study were recently announced. It met its two primary endpoints, with iptacopan demonstrating superiority over anti-C5 therapies (eculizumab or ravulizumab) in adults with PNH experiencing residual anemia despite prior anti-C5 treatment.

• The study showed a statistically significant and clinically meaningful increase in the proportion of iptacopan-treated patients achieving 2 g/dL or more hemoglobin-level increases from baseline and 12 g/dL or more hemoglobin levels without the need for blood transfusions at 24 weeks, compared to anti-C5 therapies.

• Price Action: NVS shares are down 0.81% at $90.99 on the last check Thursday.

• Photo Via Wikimedia Commons

See more from Benzinga

• MorphoSys Inks Licensing Agreement With Novartis For Preclinical Cancer Programs

• Novartis' Kisqali Prolongs Progression Free Survival Benefit In Metastatic Breast Cancer Versus Chemo

• Which Billionaire Owns The Most Land In The U.S.? Hint, It's Not Bill Gates

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.